Why Your Corrective Actions Keep Coming Back as Incomplete

Written by HATEM RABEH, MD, MSc Ing

Your Clinical Evaluation Expert And Partner

in
S

I see this pattern repeatedly. A manufacturer submits a clinical evaluation report. The Notified Body or competent authority identifies gaps. The manufacturer responds with what they call corrective actions. The response is rejected or partially accepted. The cycle repeats.

The core issue is that most corrective action responses treat clinical evaluation findings as administrative tasks rather than clinical evidence problems. The manufacturer believes the issue is a missing document or an unclear sentence. The reviewer sees a fundamental gap in clinical data, risk assessment, or conformity demonstration.

The mismatch creates delay, frustration, and often leads to major non-conformities that could have been avoided.

What Corrective Action Means in Clinical Evaluation Context

In quality management systems, corrective action typically means fixing a process that produced a non-conformity. The focus is on preventing recurrence through procedural change.

In clinical evaluation, corrective action has a different weight. It means addressing a gap in the clinical evidence base that supports your device’s safety and performance claims. This is not about updating an SOP. It is about generating, retrieving, or reinterpreting clinical data to fill a hole in your conformity demonstration.

The distinction matters because it determines what type of response will be accepted.

When a reviewer identifies insufficient clinical evidence for a particular claim or patient population, they are not asking for better writing. They are asking for clinical data that demonstrates safety and performance in that context.

If you do not have that data, your corrective action must outline how you will obtain it—whether through literature search, clinical investigation, or post-market data collection. And you must provide timelines, protocols, and interim risk mitigation measures.

The Gap Between What You Think Was Asked and What Was Actually Asked

This is where most corrective action responses fail.

A finding states: “The CER does not adequately address long-term performance beyond two years for the intended patient population.”

The manufacturer responds: “Section 7.3 of the CER will be revised to include discussion of long-term performance.”

This response misses the point entirely. The reviewer is not asking for a discussion. They are asking for clinical data that demonstrates long-term performance. If you do not have that data, no amount of revision will close the finding.

The correct response would be: “Long-term data beyond two years is not currently available in the literature for devices equivalent to ours. We have initiated a post-market clinical follow-up study to collect performance data at 3-year and 5-year intervals. The PMCF protocol is attached as Annex X. Enrollment is expected to complete by [date], with interim results available by [date]. In the meantime, risk mitigation measures include enhanced user training and updated labeling to reflect the current evidence base.”

Notice the difference. The second response acknowledges the gap, explains how it will be closed, provides timelines, and addresses interim risk management. This is what a corrective action looks like in clinical evaluation.

Why Vague Language Gets Rejected

Vague corrective actions signal that you have not understood the finding or that you are delaying a difficult decision.

Phrases like “will be updated,” “will be clarified,” or “will be addressed in the next revision” tell the reviewer nothing about what will actually change or what evidence will be provided.

Reviewers are not looking for good intentions. They are looking for specificity. What data will you add? Where will it come from? When will it be available? What criteria will you use to evaluate sufficiency?

If you cannot answer these questions in your corrective action response, you are not ready to respond.

This is not about writing skill. It is about clinical and regulatory planning. Before you respond, you need to have done the work of understanding what data gap exists, whether you can close it, and how.

The Role of Root Cause Analysis

Many corrective action responses skip root cause analysis entirely. This is a mistake.

If your CER has a gap, you need to understand why that gap exists. Was the literature search insufficient? Were equivalence criteria too narrow? Did you overlook a patient subgroup? Did you fail to integrate post-market data?

Understanding the root cause tells you what type of corrective action is needed. If the root cause is an inadequate search strategy, the corrective action is to repeat the search with broader terms and databases. If the root cause is lack of post-market data, the corrective action is to implement or enhance PMCF.

Without root cause analysis, your corrective action is likely to miss the mark.

What a Complete Corrective Action Response Looks Like

A complete corrective action response to a clinical evaluation finding includes:

1. Acknowledgment of the specific gap. Restate the finding in your own words to confirm understanding. Do not paraphrase vaguely. Be precise.

2. Root cause identification. Explain why the gap exists. Was it a methodological issue, a data availability issue, or a documentation issue?

3. Data-driven solution. Specify what clinical evidence will be added and where it will come from. If new data must be generated, provide a protocol or plan.

4. Timeline with milestones. When will the new data be available? What are the intermediate steps? Who is responsible?

5. Interim risk mitigation. If the data will take time to collect, what steps are you taking now to manage the risk identified by the finding?

6. Verification method. How will you confirm that the corrective action has successfully closed the gap? What acceptance criteria will you use?

Most responses I see include only the first and a vague version of the third. This is why they come back as incomplete.

When the Answer Is That You Cannot Close the Gap Immediately

Sometimes the honest answer is that you do not currently have the data needed to close a clinical evidence gap, and generating that data will take months or years.

This is not a failure. It is reality for many devices, especially novel ones or those used in small patient populations.

What matters is how you handle it. Do not pretend the gap does not exist. Do not claim you will address it “in the next version” without explaining how. Instead, be transparent.

Explain that the data is not available, outline your plan to collect it through PMCF or clinical investigation, and describe the interim risk management measures you are implementing. If the gap creates an unacceptable risk, you may need to modify claims, update labeling, or restrict the intended use until sufficient data is available.

Reviewers respect this approach. What they do not respect is evasion.

Integration with the Quality Management System

Corrective actions related to clinical evaluation findings must be integrated into your QMS under MDR Article 10. This means they must be documented, tracked, and verified like any other corrective action.

But the integration goes deeper. Clinical evaluation findings often reveal systemic issues—inadequate clinical data collection processes, insufficient literature monitoring, gaps in post-market surveillance, or weak equivalence justification methods.

If your corrective action only fixes the immediate finding without addressing the underlying process weakness, you will see similar findings in the next audit or the next CER update.

This is why reviewers often ask for evidence that corrective actions have been implemented across the full product portfolio, not just for the device in question.

Documentation and Traceability

Your corrective action response must be traceable. Each finding should have a unique identifier. Each response should reference that identifier and be included in the clinical evaluation documentation.

When the corrective action involves generating new data, that data must be formally incorporated into the CER in a way that directly addresses the original finding. The reviewer should be able to trace from finding to corrective action to implemented solution to verification of effectiveness.

If this traceability is not clear, the finding will remain open even if you have technically addressed it.

The Cost of Incomplete Responses

Incomplete corrective action responses create cascading delays. The certification process stalls. Market access is postponed. Resources are diverted to repeated response cycles instead of product improvement or new development.

More seriously, incomplete responses signal to the Notified Body or competent authority that your organization may not fully understand the clinical evaluation requirements under MDR. This perception can lead to increased scrutiny, more frequent audits, and a loss of trust that takes years to rebuild.

The regulatory cost is real. But the clinical cost is more important. If your corrective actions are not addressing genuine gaps in clinical evidence, you are potentially leaving patients at risk.

Moving Forward

When clinical evaluation findings arrive, resist the urge to respond quickly. Take time to understand what is actually being asked. Conduct a root cause analysis. Determine what evidence is needed and whether you have it or can obtain it.

If you need to generate new data, develop a protocol and timeline before you respond. If you need to retrieve existing data, execute the search and review the results before you commit to using them.

Only then should you draft the corrective action response. And when you do, make it specific, data-driven, and verifiable.

This approach takes more time upfront. But it eliminates the repeated response cycles, builds trust with your reviewers, and ensures that your clinical evaluation truly supports your device’s safety and performance claims.

If your corrective actions keep coming back as incomplete, the issue is not the reviewer. The issue is that you are treating clinical evidence gaps as documentation problems. They are not. They are clinical problems that require clinical solutions.

Understand the distinction, and your responses will improve. So will your clinical evaluation program.

Peace,
Hatem
Clinical Evaluation Expert for Medical Devices
Follow me for more insights and practical advice.